Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Eye Drops & Ophthalmic Recalls

Recalls of ophthalmic solutions and eye drops - a category hit by widely reported contamination recalls.

673 recalls in this category, newest first.

Class II · Moderate risk

Riboflavin 5-Phosphate Sodium Ophthalmic Solution

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Terminated Sterility / contamination Premier Pharmacy Labs Inc D-1425-2019
Class II · Moderate risk

Brilliant Blue Ophthalmic PF INJ

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

Terminated Sterility / contamination Premier Pharmacy Labs Inc D-1412-2019
Class II · Moderate risk

Red Eye

Lack of Assurance of Sterility: Product is not terminally sterialized and not tested per USP 71.

Terminated Sterility / contamination MSM Nutraceuticals, LLC D-1128-2019
Class II · Moderate risk

Dry Eye

Lack of Assurance of Sterility: Product is not terminally sterialized and not tested per USP 71.

Terminated Sterility / contamination MSM Nutraceuticals, LLC D-1127-2019
Class II · Moderate risk

15% Msm

Lack of Assurance of Sterility: Product is not terminally sterialized and not tested per USP 71.

Terminated Sterility / contamination MSM Nutraceuticals, LLC D-1126-2019
Class III · Low risk

Moxifloxacin Ophthalmic Solution USP

Failed Impurities/Degradation Specifications: Expansion of July 2018 and February 2019 recall due to high out-of-specification for impurities.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-422-01 D-0517-2019
Class II · Moderate risk

Gentamicin Sulfate Ophthalmic Solution

Failed Impurities/Degradation Specifications: High Out-of-Specification (OOS) results for Individual and Total Impurities that have been identified at the 18 months stability testing time point.

Terminated Impurity / degradation Akorn, Inc. NDC 17478-283-10 D-0993-2019
Class II · Moderate risk

Acetyl-L-Cysteine 10% P.F. Ophth Solution

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Terminated Sterility / contamination Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy D-1088-2019
Class II · Moderate risk

Dexamethasone

Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.

Terminated Sterility / contamination Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy D-1087-2019
Class III · Low risk

Moxifloxacin Ophthalmic Solution USP

Failed Impurities/Degradation Specifications: Out of specification test results in related substance at three-month long term stability study was obtained.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-422-01 D-0484-2019